Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Gastric Cancer | Primary research

miR-335-5p suppresses gastric cancer progression by targeting MAPK10

Authors: Yi Gao, Yanfeng Wang, Xiaofei Wang, Changan Zhao, Fenghui Wang, Juan Du, Huahua Zhang, Haiyan Shi, Yun Feng, Dan Li, Jing Yan, Yan Yao, Weihong Hu, Ruxin Ding, Mengjie Zhang, Lumin Wang, Chen Huang, Jing Zhang

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Background

Recent studies have established the roles of microRNAs (miRNAs) in cancer progression. The aberrant expression of miR-335-5p has been reported in many cancers, including gastric cancer (GC). In this study, the precise roles of miR-335-5p in GC as well as the molecular mechanisms underlying its effects, including the role of its target MAPK10, were evaluated.

Methods

Quantitative real-time PCR was used to evaluate miR-335-5p levels in GC cell lines and tissues. MTT and colony formation assays were used to detect cell proliferation, and Transwell and wound-healing assays were used to evaluate the invasion and migration of GC cells. The correlation between levels of miR-335-5p and the cell cycle-related target gene mitogen-activated protein kinase 10 (MAPK10) in GC was analyzed. In addition, the candidate target was evaluated by a luciferase reporter assay, qRT-PCR, and western blotting.

Results

The levels of miR-335-5p were downregulated in GC tissues and cell lines. Furthermore, miR-335-5p inhibited the proliferation and migration of GC cells and induced apoptosis. Additionally, miR-335-5p arrested the cell cycle at the G1/S phase in GC cells in vitro. Levels of miR-335-5p and the cell cycle-related target gene MAPK10 in GC were correlated, and MAPK10 was directly targeted by miR-335-5p.

Conclusions

These data suggest that miR-335-5p is a tumor suppressor and acts via MAPK10 to inhibit GC progression.
Literature
1.
2.
Lau HCH, Kranenburg O, Xiao H, Yu J. Organoid models of gastrointestinal cancers in basic and translational research. Nat Rev Gastroenterol Hepatol. 2020;17(4):203–22.PubMedCrossRef
3.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
4.
Lutz MP, Zalcberg JR, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch HI, Laurent-Puig P, Lordick F, et al. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer. 2019;112:1–8.PubMedCrossRef
5.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.PubMedCrossRef
6.
Song Y, Ye M, Zhou J, Wang Z, Zhu X. Targeting E-cadherin expression with small molecules for digestive cancer treatment. Am J Transl Res. 2019;11(7):3932–44.PubMedPubMedCentral
7.
Citron F, Segatto I, Vinciguerra GLR, Musco L, Russo F, Mungo G, D’Andrea S, Mattevi MC, Perin T, Schiappacassi M, et al. Downregulation of miR-223 expression is an early event during mammary transformation and confers resistance to CDK4/6 inhibitors in luminal breast cancer. Cancer Res. 2020;80(5):1064–77.PubMedCrossRef
8.
Liu Y, Feng J, Sun M, Yang G, Yuan H, Wang Y, Bu Y, Zhao M, Zhang S, Zhang X. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett. 2019;454:158–70.PubMedCrossRef
9.
Mukohyama J, Isobe T, Hu Q, Hayashi T, Watanabe T, Maeda M, Yanagi H, Qian X, Yamashita K, Minami H, et al. miR-221 targets QKI to enhance the tumorigenic capacity of human colorectal cancer stem cells. Cancer Res. 2019;79(20):5151–8.PubMedPubMedCentralCrossRef
10.
Tsai MM, Wang CS, Tsai CY, Huang HW, Chi HC, Lin YH, Lu PH, Lin KH. Potential diagnostic, prognostic and therapeutic targets of MicroRNAs in human gastric cancer. Int J Mol Sci. 2016;17(6):945.PubMedCentralCrossRef
11.
Jiang K, Xie LF, Xiao TZ, Qiu MY, Wang WL. MiR-181d inhibits cell proliferation and metastasis through PI3K/AKT pathway in gastric cancer. Eur Rev Med Pharmacol Sci. 2019;23(20):8861–9.PubMed
12.
Xu XL, Guo AX, Pan QY, Chang AL, Zhao CR. MiR-99a suppresses cell migration and invasion by regulating IGF1R in gastric cancer. Eur Rev Med Pharmacol Sci. 2019;23(17):7375–82.PubMed
13.
Shang JC, Yu GZ, Ji ZW, Wang XQ, Xia L. MiR-105 inhibits gastric cancer cells metastasis, epithelial-mesenchymal transition by targeting SOX9. Eur Rev Med Pharmacol Sci. 2019;23(14):6160–9.PubMed
14.
Wang M, Qiu R, Gong Z, Zhao X, Wang T, Zhou L, Lu W, Shen B, Zhu W, Xu W. miR-188-5p emerges as an oncomiRNA to promote gastric cancer cell proliferation and migration via upregulation of SALL4. J Cell Biochem. 2019;120(9):15027–37.PubMedCrossRef
15.
Zhou QY, Peng PL, Xu YH. MiR-221 affects proliferation and apoptosis of gastric cancer cells through targeting SOCS3. Eur Rev Med Pharmacol Sci. 2019;23(21):9427–35.PubMed
16.
Du W, Tang H, Lei Z, Zhu J, Zeng Y, Liu Z, Huang JA. miR-335-5p inhibits TGF-beta1-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1. Respir Res. 2019;20(1):225.PubMedPubMedCentralCrossRef
17.
Jia Q, Ye L, Xu S, Xiao H, Xu S, Shi Z, Li J, Chen Z. Circular RNA 0007255 regulates the progression of breast cancer through miR-335-5p/SIX2 axis. Thorac Cancer. 2020;11(3):619–30.PubMedPubMedCentralCrossRef
18.
Liang H, Zhang C, Guan H, Liu J, Cui Y. LncRNA DANCR promotes cervical cancer progression by upregulating ROCK1 via sponging miR-335-5p. J Cell Physiol. 2019;234(5):7266–78.PubMedCrossRef
19.
Zare A, Ahadi A, Larki P, Omrani MD, Zali MR, Alamdari NM, Ghaedi H. The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer. Mol Biol Rep. 2018;45(6):1587–95.PubMedCrossRef
20.
Yuan HL, Wang T, Zhang KH. MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer. Onco Targets Ther. 2018;11:3891–900.PubMedPubMedCentralCrossRef
21.
22.
Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. Brief Bioinform. 2014;15(1):1–19.PubMedCrossRef
23.
Kahraman M, Roske A, Laufer T, Fehlmann T, Backes C, Kern F, Kohlhaas J, Schrors H, Saiz A, Zabler C, et al. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. Sci Rep. 2018;8(1):11584.PubMedPubMedCentralCrossRef
24.
Kunde SA, Rademacher N, Tzschach A, Wiedersberg E, Ullmann R, Kalscheuer VM, Shoichet SA. Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients. Hum Genet. 2013;132(4):461–71.PubMedCrossRef
25.
Yoo KH, Park YK, Kim HS, Jung WW, Chang SG. Identification of MAPK10 as a novel epigenetic marker for chromophobe kidney cancer. Pathol Int. 2011;61(1):52–4.PubMedCrossRef
26.
Zhang L, Li H, Yuan M, Li M, Zhang S. Cervical cancer cells-secreted exosomal microRNA-221-3p promotes invasion, migration and angiogenesis of microvascular endothelial cells in cervical cancer by down-regulating MAPK10 expression. Cancer Manag Res. 2019;11:10307–19.PubMedPubMedCentralCrossRef
27.
Dai F, Zhang Y, Chen Y. Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol. 2014;45(6):1285–93.PubMedCrossRef
28.
Emami SS, Nekouian R, Akbari A, Faraji A, Abbasi V, Agah S. Evaluation of circulating miR-21 and miR-222 as diagnostic biomarkers for gastric cancer. J Cancer Res Ther. 2019;15(1):115–9.PubMed
29.
Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123(2):372–9.PubMedCrossRef
30.
Feng R, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B, Zhu Z. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010;298(1):50–63.PubMedCrossRef
31.
Kogo R, Mimori K, Tanaka F, Komune S, Mori M. Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res. 2011;17(13):4277–84.PubMedCrossRef
32.
Slattery ML, Herrick JS, Mullany LE, Valeri N, Stevens J, Caan BJ, Samowitz W, Wolff RK. An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int J Cancer. 2015;137(2):428–38.PubMedCrossRef
33.
Wang K, Jin W, Song Y, Fei X. LncRNA RP11–436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335–5p and promotes proliferation and invasion in renal cell carcinoma. Mol Cancer. 2017;16(1):166.PubMedPubMedCentralCrossRef
34.
Tang H, Zhu J, Du W, Liu S, Zeng Y, Ding Z, Zhang Y, Wang X, Liu Z, Huang J. CPNE1 is a target of miR-335-5p and plays an important role in the pathogenesis of non-small cell lung cancer. J Exp Clin Cancer Res. 2018;37(1):131.PubMedPubMedCentralCrossRef
35.
Wang Y, Zeng X, Wang N, Zhao W, Zhang X, Teng S, Zhang Y, Lu Z. Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma. Mol Cancer. 2018;17(1):89.PubMedPubMedCentralCrossRef
36.
Luo L, Xia L, Zha B, Zuo C, Deng D, Chen M, Hu L, He Y, Dai F, Wu J, et al. miR-335-5p targeting ICAM-1 inhibits invasion and metastasis of thyroid cancer cells. Biomed Pharmacother. 2018;106:983–90.PubMedCrossRef
37.
Zhang D, Yang N. MiR-335-5p inhibits cell proliferation, migration and invasion in colorectal cancer through downregulating LDHB. J BUON. 2019;24(3):1128–36.PubMed
38.
Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817–27.PubMedCrossRef
39.
Oner M, Lin E, Chen MC, Hsu FN, ShazzadHossainPrince GM, Chiu KY, Teng CJ, Yang TY, Wang HY, Yue CH, et al. Future aspects of CDK5 in prostate cancer: from pathogenesis to therapeutic implications. Int J Mol Sci. 2019;20(16):3881.PubMedCentralCrossRef
40.
Jia W, Zhao X, Zhao L, Yan H, Li J, Yang H, Huang G, Liu J. Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4. Oncogene. 2018;37(13):1685–98.PubMedCrossRef
41.
Abbosh C, Swanton C, Birkbak NJ. Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer. Ann Oncol. 2018;29(3):535–7.PubMedPubMedCentralCrossRef
42.
Bandi N, Vassella E. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011;10:55.PubMedPubMedCentralCrossRef
43.
Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008;36(16):5391–404.PubMedPubMedCentralCrossRef
44.
Zhao H, Zhang D, Yang L, Wang E. p0071 interacts with E-cadherin in the cytoplasm so as to promote the invasion and metastasis of non-small cell lung cancer. Mol Carcinog. 2018;57(1):89–96.PubMedCrossRef
45.
Wu C, Luo K, Zhao F, Yin P, Song Y, Deng M, Huang J, Chen Y, Li L, Lee S, et al. USP20 positively regulates tumorigenesis and chemoresistance through beta-catenin stabilization. Cell Death Differ. 2018;25(10):1855–69.PubMedPubMedCentralCrossRef
46.
Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288(5467):870–4.PubMedCrossRef
47.
Qiao B, Wang Q, Zhao Y, Wu J. miR-205-3p functions as a tumor suppressor in ovarian carcinoma. Reprod Sci. 2020;27(1):380–8.PubMedCrossRef
48.
Li L, Luo Z. Dysregulated miR-27a-3p promotes nasopharyngeal carcinoma cell proliferation and migration by targeting Mapk10. Oncol Rep. 2017;37(5):2679–87.PubMedPubMedCentralCrossRef
Metadata
Title
miR-335-5p suppresses gastric cancer progression by targeting MAPK10
Authors
Yi Gao
Yanfeng Wang
Xiaofei Wang
Changan Zhao
Fenghui Wang
Juan Du
Huahua Zhang
Haiyan Shi
Yun Feng
Dan Li
Jing Yan
Yan Yao
Weihong Hu
Ruxin Ding
Mengjie Zhang
Lumin Wang
Chen Huang
Jing Zhang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01684-z

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Review

The Hippo signaling pathway in leukemia: function, interaction, and carcinogenesis

Review

Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer

Primary research

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells

Primary research

Recognize the role of CD146/MCAM in the osteosarcoma progression: an in vitro study

Primary research

SCUBE3 serves as an independent poor prognostic factor in breast cancer

Primary research

LINC00221 silencing prevents the progression of hepatocellular carcinoma through let-7a-5p-targeted inhibition of MMP11
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits